Clinical trials: Cytomegalovirus
Heart Transplant Infection, CMV Infection
Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response
This study evaluates the efficacy and safety of an individualized preventive strategy against CMV infection in CMV seropositive heart transplant patients based on the specific basal response of the lymphocytes againts CMV…
- Trial name
- ELISPOT-TC (NCT04278547)
- Testing
- ELISPOT IFN-γ assay
- Where
- Spain
- Volunteers
- 188 people
- Sponsor
- Hospital Universitari de Bellvitge
Cytomegalovirus Congenital
Primary Prevention of Cytomegalovirus in Pregnancy: Addressing the Gaps (CMV GAP)
CMV is the most common congenital infection (an infection acquired before birth) in the UK. It is the leading non-genetic cause of sensorineural (inner ear) hearing loss and a common cause of neuro-disability.
- Trial name
- CMV GAP (NCT04879784)
- Testing
- No intervention
- Volunteers
- 6,000 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking…
- Trial name
- NCT06639854
- Testing
- Hematopoietic Cell Transplant, Letermovir
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme, Cytomegalovirus Infection
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue.
- Trial name
- NCT00400322
- Testing
- Valganciclovir (Valcyte)
- Where
- 3 sites in Sweden
- Volunteers
- 42 people
- Sponsor
- Karolinska Institutet
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant
T Cell Therapy of Opportunistic Cytomegalovirus Infection
The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV.
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant, Opportunistic Infections
- Trial name
- NCT02982902
- Testing
- CMV specific adoptive t-cells
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mari Dallas
Cytomegalovirus Infections, Haematological Malignancy
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient
This study consists of two parts: 1) Part 1, a retrospective part on 250 consecutive patients following allogeneic haematopoietic stem cell transplant (allo-HSCT) at the Royal Melbourne Hospital from 2012 to 2017, inclusive, and…
- Conditions
- Cytomegalovirus Infections, Haematological Malignancy, Organ or Tissue Transplant; Complications, Immune Suppression
- Trial name
- CReSCT (NCT03806764)
- Testing
- Blood sampling
- Where
- Australia
- Volunteers
- 370 people
- Sponsor
- Melbourne Health
Influenza
Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status
The study is being undertaken to evaluate responses to seasonal influenza vaccine in older adults with respect to their CMV status.
- Trial name
- CMVflu (NCT00442975)
- Testing
- Fluarix
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Public Health England
Cytomegalovirus Infections
Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive
The purpose of this study is to determine the sensitivity and specificity of QuantiFeron® and ImmuKnow® in combination for early detection of patients who will develop CMV infection in lung transplant patients with CMV-positive…
- Trial name
- REIVI (NCT02076971)
- Where
- 7 sites in Spain
- Volunteers
- 92 people
- Sponsor
- Fundacio Catalana de Pneumologia
CMV Infection
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection
The two main cytomegalovirus (CMV) prevention strategies are prophylaxis and preemptive therapy. Prophylaxis effectively prevents CMV infection after solid organ transplantation (SOT), but is associated with high rates of…
- Trial name
- NCT06341686
- Testing
- Letermovir 480 MG, Ganciclovir
- Volunteers
- 100 people
- Sponsor
- Hospital do Rim e Hipertensão
Cytomegalovirus Infection, Cytomegalovirus Disease
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult Japanese kidney transplant recipients.
- Trial name
- NCT04129398
- Testing
- Letermovir tablet, Letermovir IV
- Where
- 4 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Pregnant Women, CMV Infected Fetuses
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
The investigators' hypothesis is that maternal treatment with Letermovir will inhibit fetal CMV replication better than Valaciclovir in infected fetuses and lead to a higher proportion of negative CMV PCR at birth in neonatal…
- Trial name
- CYMEVAL3-step2 (NCT05446571)
- Testing
- Letermovir, Valacyclovir
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioblastoma Multiforme, Astrocytoma, Grade IV
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
The goal of this clinical trial is to test a combined therapy approach (allogeneic cytomegalovirus [CMV]-specific T cells and pembrolizumab) in patients with brain cancer.
- Trial name
- TCaP (NCT06157541)
- Testing
- Allogeneic cytomegalovirus-specific T cells, Pembrolizumab
- Where
- 4 sites in Australia
- Volunteers
- 58 people
- Sponsor
- Queensland Institute of Medical Research
Cytomegalovirus Infections
Recombinant CMV gB Vaccine in Postpartum Women
The purpose of this study is to determine if a new cytomegalovirus (CMV) vaccine (CMV gB/MF59) can safely prevent mothers from catching CMV infection between pregnancies.
- Trial name
- NCT00125502
- Testing
- CMV gB vaccine, MF59 adjuvant
- Where
- 2 sites in United States
- Volunteers
- 464 people, healthy volunteers welcome
- Sponsor
- Robert Pass, MD
Malignant Neoplasms Brain
Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
RATIONALE: Monoclonal antibodies, such as basiliximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- REGULATe (NCT00626483)
- Testing
- RNA-loaded dendritic cell vaccine, basiliximab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Gary Archer Ph.D.
Viraemia
Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
This study aims to determine: a) whether those patients with 'low level' viral load results (between 200 and 3,000 copies/ml) could be monitored as opposed to starting preemptive therapy with valganciclovir, ganciclovir and/or…
- Trial name
- NCT00947141
- Testing
- ganciclovir (start when CMV PCR >200copies / ml x2), Monitor (Treatment starts when CMV PCR >3,000 copies / ml), Stop treatment when 2 levels CMV PCR <3,000 copies / ml
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- University College, London
Healthy Adult Subjects
Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers
The purpose of this study is to determine the safety and pharmacokinetics following a single oral dose of MBX-400.
- Trial name
- NCT01433835
- Testing
- MBX-400
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Microbiotix, Inc.
Infections, Cytomegalovirus
Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects
This will be the first time in humans (FTIH) study with the GSK Bio recombinant gB antigen to evaluate safety and immunogenicity of this CMV candidate vaccine with a proprietary GSK adjuvant system.
- Trial name
- NCT00435396
- Testing
- GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A
- Where
- 2 sites in Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus
The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease
This pilot study is to assess whether using CytoGam® in combination with ganciclovir is more effective in reducing the CMV viral load over time, as compared to standard treatment with IV ganciclovir only.
- Trial name
- NCT00214240
- Testing
- CMV Immune globulin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Wisconsin, Madison
Cytomegalovirus (CMV), Inflammatory Bowel Disease (IBD)
Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases
Observational, single-center, non-pharmacological, prospective study of adult patients affected by Inflammatory Bowel Disease (IBD) with an ongoing disease exacerbation requiring hospitalization
- Trial name
- CYTO-BOLD (NCT06793124)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna